News articles about Codexis (NASDAQ:CDXS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Codexis earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.3514418577985 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

CDXS has been the topic of several research analyst reports. BidaskClub upgraded shares of Codexis from a “hold” rating to a “buy” rating in a research note on Friday, December 15th. Jefferies Group lifted their price target on shares of Codexis from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Friday, October 13th. Zacks Investment Research upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.50 price target on shares of Codexis in a research note on Tuesday, November 21st. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $7.81.

Shares of Codexis (CDXS) opened at $8.60 on Thursday. Codexis has a one year low of $3.60 and a one year high of $9.45. The company has a market cap of $410.95, a price-to-earnings ratio of -13.23 and a beta of -1.59.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.05). Codexis had a negative return on equity of 140.02% and a negative net margin of 76.37%. research analysts expect that Codexis will post -0.46 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at

About Codexis

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with's FREE daily email newsletter.